Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386318273> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W4386318273 abstract "Abstract Background Despite trimodality treatment, 10–20% of patients with esophageal cancer develop metastases after surgery. Re-staging after neoadjuvant chemoradiotherapy (nCRT) may be useful to identify these patients who should not have proceeded to surgery. In this multicenter observational cohort study, we assessed the proportion of patients with interval metastases after nCRT. Secondary outcomes were overall survival (OS), location and treatment of metastases. Methods Between 2013–2021, patients with cT2-4aN0–3 M0 esophageal/junctional cancer who underwent nCRT were identified from three prospective study-databases. Re-staging with 18F-FDG-PET/CT ≤14 weeks after completion of nCRT was performed in all patients. Metastases detected on imaging or during surgery were categorized into oligometastatic (≤3 lesions located in one single organ or in one extra-regional lymph node station) or non-oligometastatic. Treatment of metastases was based on pretreatment multidisciplinary tumor board reports for patients with oligometastatic disease and consisted of systemic therapy, loco(regional) therapy or best supportive care. OS was calculated from completion of nCRT until date of death or last day of follow-up. Results Metastases were detected in 100 of 973 patients (10.3%). The majority (84%) were detected by 18F-FDG-PET/CT and in 16% during surgery of which 60% were peritoneal metastases. Oligometastatic disease was seen in 30% of patients and 12 patients (40%) were treated with potentially curative intent. Median OS of patients with oligometastatic disease who were treated with potentially curative intent was 22.8 months (95% CI 10.4-NA), compared to 13.8 months (95% CI 9.2–27.1) in patients treated with palliative intent. Oligometastases were mostly located in non-regional lymph nodes (33.3%) or bones (26.7%). Median OS non-oligometastatic disease 9.0 months (95% CI 7.4–10.9). Conclusion Interval metastases were detected in about 10% of esophageal cancer patients after nCRT and the majority had non-oligometastatic disease. This underlines the benefit of restaging to select patients who are not candidates for esophagectomy. Treatment of oligometastases might lead to favorable survival in selected patients." @default.
- W4386318273 created "2023-09-01" @default.
- W4386318273 creator A5007311016 @default.
- W4386318273 creator A5012955240 @default.
- W4386318273 creator A5017643108 @default.
- W4386318273 creator A5020120535 @default.
- W4386318273 creator A5020972269 @default.
- W4386318273 creator A5021822394 @default.
- W4386318273 creator A5021834422 @default.
- W4386318273 creator A5025225016 @default.
- W4386318273 creator A5025826957 @default.
- W4386318273 creator A5028436331 @default.
- W4386318273 creator A5029196683 @default.
- W4386318273 creator A5037535575 @default.
- W4386318273 creator A5041873426 @default.
- W4386318273 creator A5052145533 @default.
- W4386318273 creator A5060123408 @default.
- W4386318273 creator A5064280092 @default.
- W4386318273 creator A5072405531 @default.
- W4386318273 creator A5072902637 @default.
- W4386318273 creator A5073590182 @default.
- W4386318273 creator A5078561640 @default.
- W4386318273 date "2023-08-30" @default.
- W4386318273 modified "2023-10-02" @default.
- W4386318273 title "221. INTERVAL METASTASES AFTER NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL CANCER: A MULTICENTER OBSERVATIONAL COHORT STUDY" @default.
- W4386318273 doi "https://doi.org/10.1093/dote/doad052.074" @default.
- W4386318273 hasPublicationYear "2023" @default.
- W4386318273 type Work @default.
- W4386318273 citedByCount "0" @default.
- W4386318273 crossrefType "journal-article" @default.
- W4386318273 hasAuthorship W4386318273A5007311016 @default.
- W4386318273 hasAuthorship W4386318273A5012955240 @default.
- W4386318273 hasAuthorship W4386318273A5017643108 @default.
- W4386318273 hasAuthorship W4386318273A5020120535 @default.
- W4386318273 hasAuthorship W4386318273A5020972269 @default.
- W4386318273 hasAuthorship W4386318273A5021822394 @default.
- W4386318273 hasAuthorship W4386318273A5021834422 @default.
- W4386318273 hasAuthorship W4386318273A5025225016 @default.
- W4386318273 hasAuthorship W4386318273A5025826957 @default.
- W4386318273 hasAuthorship W4386318273A5028436331 @default.
- W4386318273 hasAuthorship W4386318273A5029196683 @default.
- W4386318273 hasAuthorship W4386318273A5037535575 @default.
- W4386318273 hasAuthorship W4386318273A5041873426 @default.
- W4386318273 hasAuthorship W4386318273A5052145533 @default.
- W4386318273 hasAuthorship W4386318273A5060123408 @default.
- W4386318273 hasAuthorship W4386318273A5064280092 @default.
- W4386318273 hasAuthorship W4386318273A5072405531 @default.
- W4386318273 hasAuthorship W4386318273A5072902637 @default.
- W4386318273 hasAuthorship W4386318273A5073590182 @default.
- W4386318273 hasAuthorship W4386318273A5078561640 @default.
- W4386318273 hasBestOaLocation W43863182731 @default.
- W4386318273 hasConcept C121608353 @default.
- W4386318273 hasConcept C126322002 @default.
- W4386318273 hasConcept C126838900 @default.
- W4386318273 hasConcept C141071460 @default.
- W4386318273 hasConcept C143998085 @default.
- W4386318273 hasConcept C188816634 @default.
- W4386318273 hasConcept C23131810 @default.
- W4386318273 hasConcept C2778292576 @default.
- W4386318273 hasConcept C2778424827 @default.
- W4386318273 hasConcept C2779742542 @default.
- W4386318273 hasConcept C2780849966 @default.
- W4386318273 hasConcept C509974204 @default.
- W4386318273 hasConcept C530470458 @default.
- W4386318273 hasConcept C71924100 @default.
- W4386318273 hasConcept C72563966 @default.
- W4386318273 hasConceptScore W4386318273C121608353 @default.
- W4386318273 hasConceptScore W4386318273C126322002 @default.
- W4386318273 hasConceptScore W4386318273C126838900 @default.
- W4386318273 hasConceptScore W4386318273C141071460 @default.
- W4386318273 hasConceptScore W4386318273C143998085 @default.
- W4386318273 hasConceptScore W4386318273C188816634 @default.
- W4386318273 hasConceptScore W4386318273C23131810 @default.
- W4386318273 hasConceptScore W4386318273C2778292576 @default.
- W4386318273 hasConceptScore W4386318273C2778424827 @default.
- W4386318273 hasConceptScore W4386318273C2779742542 @default.
- W4386318273 hasConceptScore W4386318273C2780849966 @default.
- W4386318273 hasConceptScore W4386318273C509974204 @default.
- W4386318273 hasConceptScore W4386318273C530470458 @default.
- W4386318273 hasConceptScore W4386318273C71924100 @default.
- W4386318273 hasConceptScore W4386318273C72563966 @default.
- W4386318273 hasIssue "Supplement_2" @default.
- W4386318273 hasLocation W43863182731 @default.
- W4386318273 hasOpenAccess W4386318273 @default.
- W4386318273 hasPrimaryLocation W43863182731 @default.
- W4386318273 hasRelatedWork W2168952713 @default.
- W4386318273 hasRelatedWork W2249625608 @default.
- W4386318273 hasRelatedWork W2363456260 @default.
- W4386318273 hasRelatedWork W2392540188 @default.
- W4386318273 hasRelatedWork W2404042595 @default.
- W4386318273 hasRelatedWork W2415196927 @default.
- W4386318273 hasRelatedWork W2417835388 @default.
- W4386318273 hasRelatedWork W2419203947 @default.
- W4386318273 hasRelatedWork W2771740032 @default.
- W4386318273 hasRelatedWork W3090963952 @default.
- W4386318273 hasVolume "36" @default.
- W4386318273 isParatext "false" @default.
- W4386318273 isRetracted "false" @default.
- W4386318273 workType "article" @default.